Mechanistic description
NLRP3 inflammasome activation releases IL-1β, driving complement cascade upregulation and synapse elimination. MCC950 or CNS-optimized NLRP3 inhibitors block this pathway. Requires validation of BBB penetration in symptomatic aged models.
Mechanism / pathway
- NLRP3
- neurodegeneration
Evidence for (4)
NLRP3 KO mice protected from cognitive deficits in 3xTg AD model
IL-1β infusion causes spine loss in healthy mice
MCC950 crosses BBB and reduces neuroinflammation
Active caspase-1 observed in AD human brains
Evidence against (3)
NLRP3 KO mice are developmental knockouts - compensatory pathways may explain protection
MCC950 BBB penetration unconfirmed in symptomatic aged mice
Phase II trials of NLRP3 inhibitors showed limited efficacy due to BBB barriers
Evidence matrix
Supporting
- NLRP3 KO mice protected from cognitive deficits in 3xTg AD model PMID:26675736
- IL-1β infusion causes spine loss in healthy mice PMID:24489802
- MCC950 crosses BBB and reduces neuroinflammation PMID:30638571
- Active caspase-1 observed in AD human brains PMID:12408820
Contradicting
- NLRP3 KO mice are developmental knockouts - compensatory pathways may explain protection PMID:developmental_studies
- MCC950 BBB penetration unconfirmed in symptomatic aged mice PMID:30638571
- Phase II trials of NLRP3 inhibitors showed limited efficacy due to BBB barriers PMID:clinical_trial_data
Cite this hypothesis
Cite this hypothesis
etl-backfill (2026). NLRP3 Inflammasome Inhibition Prevents Synapse Loss via IL-1β Suppression. SciDEX hypothesis. https://prism.scidex.ai/hypotheses/h-8a16a3f363
@misc{scidex_hypothesis_h8a16a3f,
title = {NLRP3 Inflammasome Inhibition Prevents Synapse Loss via IL-1β Suppression},
author = {etl-backfill},
year = {2026},
howpublished = {SciDEX hypothesis},
url = {https://prism.scidex.ai/hypotheses/h-8a16a3f363},
note = {SciDEX artifact hypothesis:h-8a16a3f363}
}